Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.

Lobectomy is the standard curative treatment for non-small cell carcinoma (NSCLC) of the lung. Most studies on lobectomy have focused on short-term outcome and 30-day mortality. The aim of this study was to determine both short-term and long-term surgical outcome in all patients who underwent lobect...

Full description

Bibliographic Details
Published in:Acta Oncologica
Main Authors: Oskarsdottir, G N, Halldorsson, H, Sigurdsson, M I, Fridriksson, B M, Baldvinsson, K, Orrason, A W, Jonsson, S, Planck, M, Gudbjartsson, T
Other Authors: 1 Landspitali Univ Hosp, Dept Cardiothorac Surg, Reykjavik, Iceland Show the Organization-Enhanced name(s) 2 Skane Univ Hosp, Dept Pulmonol, Lund, Sweden Show the Organization-Enhanced name(s) 3 Landspitali Univ Hosp, Dept Pulmonol, Reykjavik, Iceland Show the Organization-Enhanced name(s) 4 Univ Iceland, Fac Med, Reykjavik, Iceland
Format: Article in Journal/Newspaper
Language:English
Published: Taylor & Francis 2017
Subjects:
TNM
Online Access:http://hdl.handle.net/2336/620219
https://doi.org/10.1080/0284186X.2017.1304652
id ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/620219
record_format openpolar
spelling ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/620219 2023-05-15T16:48:03+02:00 Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival. Oskarsdottir, G N Halldorsson, H Sigurdsson, M I Fridriksson, B M Baldvinsson, K Orrason, A W Jonsson, S Planck, M Gudbjartsson, T 1 Landspitali Univ Hosp, Dept Cardiothorac Surg, Reykjavik, Iceland Show the Organization-Enhanced name(s) 2 Skane Univ Hosp, Dept Pulmonol, Lund, Sweden Show the Organization-Enhanced name(s) 3 Landspitali Univ Hosp, Dept Pulmonol, Reykjavik, Iceland Show the Organization-Enhanced name(s) 4 Univ Iceland, Fac Med, Reykjavik, Iceland 2017-07 http://hdl.handle.net/2336/620219 https://doi.org/10.1080/0284186X.2017.1304652 en eng Taylor & Francis http://www.tandfonline.com/doi/pdf/10.1080/0284186X.2017.1304652?needAccess=true Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival. 2017, 56 (7):936-942 Acta Oncol 1651-226X 28325129 doi:10.1080/0284186X.2017.1304652 http://hdl.handle.net/2336/620219 Acta oncologica (Stockholm, Sweden) Archived with thanks to Acta oncologica (Stockholm, Sweden) Landspitali Access - LSH-aðgangur Lungnakrabbamein Brjóstholsskurðlækningar Skurðlækningar Lífslíkur TAS12 PAD12 Pulmonary Surgical Procedures Patient Outcome Assessment Survival Carcinoma Non-Small-Cell Lung Article 2017 ftlandspitaliuni https://doi.org/10.1080/0284186X.2017.1304652 2022-05-29T08:22:15Z Lobectomy is the standard curative treatment for non-small cell carcinoma (NSCLC) of the lung. Most studies on lobectomy have focused on short-term outcome and 30-day mortality. The aim of this study was to determine both short-term and long-term surgical outcome in all patients who underwent lobectomy for NSCLC in Iceland over a 24-year period. The study involved 489 consecutive patients with NSCLC who underwent lobectomy with curative intent in Iceland, 1991-2014. Patient demographics, pTNM stage, rate of perioperative complications, and 30-day mortality were registered. Overall survival was analyzed with the Kaplan?Meier method. The Cox proportional hazards model was used to evaluate factors that were prognostic of overall mortality. To study trends in survival, the study period was divided into six 4-year periods. The median follow-up time was 42 months and no patients were lost to follow-up. The average age of the patients was 67 years and 53.8% were female. The pTNM disease stage was IA in 148 patients (30.0%), IB in 125 patients (25.4%), IIA in 96 patients (19.5%), and IIB in 50 patients (10.1%), but 74 (15.0%) were found to be stage IIIA, most often diagnosed perioperatively. The total rate of major complications was 4.7%. Thirty-day mortality was 0.6% (three patients). One- and 5-year overall survival was 85.0% and 49.2%, respectively, with 3-year survival improving from 48.3% to 72.8% between the periods 1991-1994 and 2011-2014 (p = .0004). Advanced TNM stage and age were independent negative prognostic factors for all-cause mortality, and later calendar year and free surgical margins were independent predictors of improved survival. The short-term outcome of lobectomy for NSCLC in this population-based study was excellent, as reflected in the low 30-day mortality and low rate of major complications. The long-term survival was acceptable and the overall 3-year survival had improved significantly during the study period. Landspitali University Hospital Research Fund University of Iceland ... Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive Meier ENVELOPE(-45.900,-45.900,-60.633,-60.633) TNM ENVELOPE(-58.100,-58.100,-62.000,-62.000) Acta Oncologica 56 7 936 942
institution Open Polar
collection Hirsla - Landspítali University Hospital research archive
op_collection_id ftlandspitaliuni
language English
topic Lungnakrabbamein
Brjóstholsskurðlækningar
Skurðlækningar
Lífslíkur
TAS12
PAD12
Pulmonary Surgical Procedures
Patient Outcome Assessment
Survival
Carcinoma
Non-Small-Cell Lung
spellingShingle Lungnakrabbamein
Brjóstholsskurðlækningar
Skurðlækningar
Lífslíkur
TAS12
PAD12
Pulmonary Surgical Procedures
Patient Outcome Assessment
Survival
Carcinoma
Non-Small-Cell Lung
Oskarsdottir, G N
Halldorsson, H
Sigurdsson, M I
Fridriksson, B M
Baldvinsson, K
Orrason, A W
Jonsson, S
Planck, M
Gudbjartsson, T
Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.
topic_facet Lungnakrabbamein
Brjóstholsskurðlækningar
Skurðlækningar
Lífslíkur
TAS12
PAD12
Pulmonary Surgical Procedures
Patient Outcome Assessment
Survival
Carcinoma
Non-Small-Cell Lung
description Lobectomy is the standard curative treatment for non-small cell carcinoma (NSCLC) of the lung. Most studies on lobectomy have focused on short-term outcome and 30-day mortality. The aim of this study was to determine both short-term and long-term surgical outcome in all patients who underwent lobectomy for NSCLC in Iceland over a 24-year period. The study involved 489 consecutive patients with NSCLC who underwent lobectomy with curative intent in Iceland, 1991-2014. Patient demographics, pTNM stage, rate of perioperative complications, and 30-day mortality were registered. Overall survival was analyzed with the Kaplan?Meier method. The Cox proportional hazards model was used to evaluate factors that were prognostic of overall mortality. To study trends in survival, the study period was divided into six 4-year periods. The median follow-up time was 42 months and no patients were lost to follow-up. The average age of the patients was 67 years and 53.8% were female. The pTNM disease stage was IA in 148 patients (30.0%), IB in 125 patients (25.4%), IIA in 96 patients (19.5%), and IIB in 50 patients (10.1%), but 74 (15.0%) were found to be stage IIIA, most often diagnosed perioperatively. The total rate of major complications was 4.7%. Thirty-day mortality was 0.6% (three patients). One- and 5-year overall survival was 85.0% and 49.2%, respectively, with 3-year survival improving from 48.3% to 72.8% between the periods 1991-1994 and 2011-2014 (p = .0004). Advanced TNM stage and age were independent negative prognostic factors for all-cause mortality, and later calendar year and free surgical margins were independent predictors of improved survival. The short-term outcome of lobectomy for NSCLC in this population-based study was excellent, as reflected in the low 30-day mortality and low rate of major complications. The long-term survival was acceptable and the overall 3-year survival had improved significantly during the study period. Landspitali University Hospital Research Fund University of Iceland ...
author2 1 Landspitali Univ Hosp, Dept Cardiothorac Surg, Reykjavik, Iceland Show the Organization-Enhanced name(s) 2 Skane Univ Hosp, Dept Pulmonol, Lund, Sweden Show the Organization-Enhanced name(s) 3 Landspitali Univ Hosp, Dept Pulmonol, Reykjavik, Iceland Show the Organization-Enhanced name(s) 4 Univ Iceland, Fac Med, Reykjavik, Iceland
format Article in Journal/Newspaper
author Oskarsdottir, G N
Halldorsson, H
Sigurdsson, M I
Fridriksson, B M
Baldvinsson, K
Orrason, A W
Jonsson, S
Planck, M
Gudbjartsson, T
author_facet Oskarsdottir, G N
Halldorsson, H
Sigurdsson, M I
Fridriksson, B M
Baldvinsson, K
Orrason, A W
Jonsson, S
Planck, M
Gudbjartsson, T
author_sort Oskarsdottir, G N
title Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.
title_short Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.
title_full Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.
title_fullStr Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.
title_full_unstemmed Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.
title_sort lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival.
publisher Taylor & Francis
publishDate 2017
url http://hdl.handle.net/2336/620219
https://doi.org/10.1080/0284186X.2017.1304652
long_lat ENVELOPE(-45.900,-45.900,-60.633,-60.633)
ENVELOPE(-58.100,-58.100,-62.000,-62.000)
geographic Meier
TNM
geographic_facet Meier
TNM
genre Iceland
genre_facet Iceland
op_relation http://www.tandfonline.com/doi/pdf/10.1080/0284186X.2017.1304652?needAccess=true
Lobectomy for non-small cell lung carcinoma: a nationwide study of short- and long-term survival. 2017, 56 (7):936-942 Acta Oncol
1651-226X
28325129
doi:10.1080/0284186X.2017.1304652
http://hdl.handle.net/2336/620219
Acta oncologica (Stockholm, Sweden)
op_rights Archived with thanks to Acta oncologica (Stockholm, Sweden)
Landspitali Access - LSH-aðgangur
op_doi https://doi.org/10.1080/0284186X.2017.1304652
container_title Acta Oncologica
container_volume 56
container_issue 7
container_start_page 936
op_container_end_page 942
_version_ 1766038157440057344